Association of Immune Checkpoint Inhibitors With Neurologic Adverse Events: A Systematic Review and Meta-analysis.

ABSTRACT:

Importance

Neurologic adverse events (NAEs) due to immune checkpoint inhibitors (ICIs) can be fatal but are underexplored.

Objective

To compare NAEs reported in randomized clinical trials (RCTs) of US Food and Drug Administration-approved ICIs with other forms of chemotherapy and placebo.

Data sources

Bibliographic databases (Embase, Ovid, MEDLINE, and Scopus data) and trial registries (ClinicalTrials.gov) were searched from inception through March 1, 2020.

Study selection

Phase II/III RCTs evaluating the use of ICIs were eligible for inclusion. Unpublished trials were excluded from the analysis.

Data extraction and synthesis

Two investigators independently performed screening of trials using the Preferred Reporting Items for Systematic Reviews and Meta-

SUBMITTER: Farooq MZ 

PROVIDER: S-EPMC9020216 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature